A WOMAN has shared how she lost a staggering 9.5 stone being on Mounjaro, but said there was a dark side that no one talks ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Losing weight and sustaining a healthy weight are notoriously difficult. If you’re struggling to reach your weight goals, you ...

PACKING for her holidays Ann Howard wonders whether to put her bikini into her suitcase. She might have shed three stone after taking fat jabs but she knows deep down that the idea of wearing a ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

Experts have issued an urgent warning about a symptom that can come to light from taking drugs such as Mounjaro and Ozempic.